RBC Capital reduced Westlake's price target to $170 and maintains an Outperform rating due to weak market conditions in chlorovinyls. Earnings expectations for the second half of 2024 have decreased, impacted by Europe weakness and unplanned outages.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing